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Tumor suppressor genesThe extent of focal chromosomal copy number aberrations (CNAs) in cancer has been uncovered through
technical innovations, and this discovery has been critical for the identiﬁcation of new cancer driver genes in
genomics projects such as TCGA and ICGC. Unlike constitutive copy number variations (CNVs), focal CNAs are
the result of many selection events during the evolution of cancer genomes. Therefore, it is possible that a single
gene in a focal CNA gives the tumor a selective growth advantage. This concept has been instrumental in the
discovery of new cancer driver genes. However, focal CNAs lack a consensus deﬁnition; therefore, we propose
one based on pragmatic considerations. We also describe different strategies to identify focal CNAs and
procedures to distinguish them from large CNAs and CNVs.
© 2014 Elsevier B.V. All rights reserved.Deﬁnition of key terms
Genomic aberration versus variation In this article, aberration refers to
acquired changes in the tumor genome in comparison to the
healthy genome; variation refers to germ line differences
between healthy individuals that are inherited.
Copy number aberration (CNA) An acquired numerical change of a
chromosome or chromosomal segment in comparison with
a reference genome.
Focal CNA CNA of limited size, frequently enriched for cancer driver
genes (described in this review).
Copy number variation (CNV) A numerical difference of a chromosomal
segment present in the germ line in comparison with a refer-
ence genome. The database of genomic variants (http://dgv.
tcag.ca/) states that a CNV is between 1 kb and 3 Mb [1].
Single nucleotide polymorphism arrays (SNP arrays) A type of DNA
microarray initially developed for genome-wide testing of
SNPs, but later applied for DNA copy number detection by
comparing the ﬂuorescence signal strength of each spot on
the array to an external control reference.
Array comparative genomic hybridization (arrayCGH) A type of DNA
microarray developed for copy number detection; arrayCGHVU University Medical Center,
nds. Tel.: +31 20 4442495;
), b.carvalho@vumc.nl
gen@vumc.nlcompares the ﬂuorescence signal strength of a test sample
to a reference for each spot on the array.
Next generation sequencing (NGS) or massively parallel sequencing
(MPS) High-throughput sequencing techniques that can be
applied for copy number detection. The most commonly
used method is a depth-of-coverage (DOC) method, which
infers the copy number from the observed sequence depth
across the genome.
Karyotyping Microscope-based test to examine chromosomes for
quantitative and structural changes in cells; the techniques
can be used to identify genetic problems such as the cause
of a disorder or disease.
Gain and ampliﬁcation Presence of multiple copies of a chromosome or
chromosomal segment. An ampliﬁcation is a high-level gain
of a chromosomal segment (frequently deﬁnedas 8 copies) [2].
Loss/deletion Decrease in copy number of a chromosome or
chromosomal segment.
Driver versus passenger Each cancer is characterized by numerous
aberrations in its genome. Only a subset of these aberrations
contributes to the tumor initiation and progression.
Contributing aberrations are referred to as ‘drivers’, the
non-contributing aberrations as ‘passengers’ [3].
1. Discovery through technical innovation
At the end of the 19th century, microscopes with a resolution that
allowed visualization of chromosomes were developed. Initial reports
estimated that the number of chromosomes in human cells of somatic
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20th century led to more accurate estimates and the assertion that,
similar to chimpanzees, humans have 48 chromosomes per cell. The
deﬁnitive answer that diploid human cells have 46 chromosomes
came in 1955 thanks to Tijo and Levan [4], well after the discovery of
the structure of DNA [5]. Before the exact number of chromosomes
was determined, deviations in cell divisions, nuclear segregations and
chromosome number were already observed in cancer cells (reviewed
in [6]), leading to the idea that cancer is a genetic disease. (We now
know cancer is marked by chromosomal aberrations, both on the nu-
merical as well as on the structural level.) The ﬁrst well-documented
structural anomaly in cancer was the discovery of the “Philadelphia
chromosome” [7]. This abnormally small chromosome was observed
in chronic myelogenous leukemia (CML); it arises due to a reciprocal
translocation between chromosomes 9 and 22, which results in the
fusion of the genes BCR and ABL [8].
With the development of techniques such as chromosomal banding
in the 1960s, and FISH in the early 1980s, cytogenetic analysis became
more informative and gross chromosomal abnormalities, both nu-
merical and structural, could be studied in more detail [9]. Two
examples frequently observed in cancer and readily identiﬁed by
chromosome banding are homogeneously staining regions (HSRs) andFig. 1. Example of a focal deletion in a colon cancer specimen. Tumor DNAwas isolated from FFP
shows the complete genome. Panel B shows chromosome 10with a focal deletion around the 90
92Mb. In this region, a deletion of ~0.7 Mb is visible. In addition to a deletion of thewell-known
is present.doubleminutes (DM),which are ampliﬁed inter- and extrachromosomal
segments, respectively [10,11].
In the early 1990s, the development of a new technique, compara-
tive genomic hybridization (CGH), enabled the detection of DNA copy
number aberrations (CNAs) on a genome-wide scale, without the
need for preparing metaphase spreads from the cells being analyzed
[12–14]. The CGH technique was soon superseded by microarray-
based CGH (arrayCGH), which allowed for even higher resolving
power [15,16]. This technical innovation allowed the genome-wide
detection of CNAs smaller than 5 Mb as well as high-resolution
genome-wide detection of CNAs in formalin-ﬁxed parafﬁn-embedded
(FFPE) specimens (for an example, see Fig. 1). The spatial resolving
power of arrays progressively increased through the introduction
of new array types and higher probe density [17–21]. Individually
cloned and grown DNA constructs, like phage- and bacterial artiﬁcial
chromosomes (PACs and BACs), were replaced by synthetic oligonucle-
otides [20]; the latest commercial arrays now have over a million in situ
synthesized oligonucleotides, enabling the detection of genomic
aberrations in the kilobase range [21].
The increased spatial resolving power of chromosomal copy number
detection techniques led to two discoveries. First, genomes in the
healthy population contain a much larger amount of copy numberE archival tissue and analyzedwith a 180 K CGH array (Agilent Technologies) [34]. Panel A
Mb. Panel C is a zoom-in on the region of chromosome 10 frombase pair position 88Mb to
tumor suppressor gene PTEN, a second gene, RNLS, not previously associatedwith cancer,
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of focal CNAs was observed in cancer. Focal CNAs are similar in size to
CNVs and were observed in many different cancer types.
One of the ﬁrst reports that demonstrated the abundance of
focal CNAs studied non-small cell lung cancer cell lines (NSCLC) using
arrayCGHwith 32,000 BAC clones [25]. Focal CNAs in these NSCLC sam-
ples frequently revealed gain of c-MYC and loss of FHIT [25]. A year later,
Weir et al. analyzed focal CNAs from a series of lung adenocarcinomas
using high-resolution single nucleotide polymorphism (SNP) arrays
[26]. They reported 31 highly recurrent focal CNAs in a series of
371 lung tumors analyzed with the GISTIC algorithm [27]. The most
common focal CNA was observed at chromosome 14q13.3 (~0.5 Mb)
in ~12% of samples and involved2 genes,MBIP andNKX2-1. Other recur-
rent focal CNAs observed in this study included well-known cancer
genes such as EGFR, PTEN, KRAS and CDKN2A as well as genes that
were not associated with cancer at the time, such as PTPRD and VEGFA.
More publications soon followed for other cancer types, suggesting
that focal CNAs are a widespread phenomenon. Leary et al. ﬁrst
described the frequency of focal CNAs in patient samples; using high-
resolution SNP arrays, they observed an average of 7 and 18 focal
CNAs in colon and breast cancers, respectively [28]. Some focal CNAs
overlapped between tumor types, others were tumor type-speciﬁc;
losses of CDH20 and PTENwere observed in both tumor types, whereas
ampliﬁcations seemed more tumor type-speciﬁc, such as EGFR and
MAP2K4 in colon cancer and ERBB2 in breast cancer. An example of a
focal CNA of PTEN in a colon cancer detected by arrayCGH is presented
in Fig. 1.
The most recent technological innovation for the detection of DNA
copy number changes is next generation sequencing (NGS) [29,30].
Copy number detection has been performed on both whole-genome
and targeted NGS data, and gains and losses of single exons have been
reported [31,32]. In theory, NGS allows for the ultimate resolution
in the detection of CNAs, but needs inclusion of patient-matched
germ line DNA.
2. Boundary between large and focal CNAs
The term ‘focal CNAs’ has been used without a strict consensus.
Many laboratories, including our own, have deﬁned an exact upper
cutoff size value, of either 1 Mb [33] or 3 Mb [34]. Others have used
‘smaller than a chromosome-arm’ to deﬁne a focal CNA [27,35,36].
Alternative operational cutoffs for focal CNAs could be: ‘CNAs that
contain maximally one annotated element’, or ‘CNAs that are peaks,
statistically recognized by a particular algorithm, e.g. GISTIC or CGHcall’
[26,27,35–37]. The key question is whether focal CNAs are at the far
end of a continuous spectrum, or whether they form a separate entity.
To address this question, we plotted the size distribution of CNAs from
a large sample set of publicly available high-resolution copy number
data, speciﬁcally 331 gastrointestinal cancer samples (esophageal,
gastric and colon) [38]. In addition, we plotted the size distribution of
CNVs from 270 blood samples of healthy individuals (HapMap). Both
samples sets were analyzed on the same platform with identical
segmentation, calling algorithms and settings [39,40]. Copy number
changes were detected in the cancer samples ranging in size from
whole chromosomes to as little as a few kilobases (the lower limit
detectable with this type of SNP arrays). With the control HapMap
samples, copy number changes were observed ranging in size from
~3Mb to as little as a few kilobases [1], very similar to those reported
in the database of genomic variants (http://dgv.tcag.ca/) (Fig. 2). For the
size-distribution graph of copy number changes in the cancer samples,
no clear shoulder was observed, other than an increase below ~3 Mb.
This increase is in the size range of CNVs, which were detected in the
cancer samples in parallel with focal CNAs (Fig. 3). Different window
sizes for the distribution of CNAs and CNVs were evaluated, but none
of these analyses provided evidence for a biological basis of focal CNAs
as a distinct entity.Since there is no basis for a biological deﬁnition, we favor a size
deﬁnition of 3 Mb, which is strictly operational and motivated by
the following considerations: 1) over 99% of germ line copy number
changes, thus CNVs, are ≤3 Mb; 2) a region of 3 Mb in the human
genome contains no, one or only a few genes, enabling cancer gene
discovery; and 3) ≤1 − 3 Mb is already frequently used to deﬁne
focal CNAs in literature [28,33,34].3. Bioinformatical approaches for the automated detection and
calling of focal CNAs
Interpretation of high-resolution copy number data from tumor
samples comprises multiple steps and is therefore a bioinformatical
challenge. First, the detection of CNAs requires a distinction between
(technical) noise and biological signals [41]. Second, as discussed
above, focal CNAs overlap with CNVs, so they need to be distinguished
from each other. Surprisingly, despite the opportunities focal CNAs
provide for determining biological mechanisms, only a limited number
of software tools are currently available for the dedicated analysis of
focal CNAs, often in large series of samples.
A widely used software package for copy number analysis was
developed at the Broad Institute and is called GISTIC, later superseded
by GISTIC2.0 [26,27,37]. Identiﬁcation of recurrent aberrations by
GISTIC is based on the likelihood of the aberration occurring by chance.
Although improved in GISTIC2.0, the probability score is highly affected
by the amplitude of aberrations in individual samples and the frequency
in the sample series. Furthermore, GISTIC2.0 is geared towards the iden-
tiﬁcation of genes. Consequently, this method prioritizes ampliﬁcations
and homozygous deletions over recurrent single CNAs [27,35]. Genomic
regions without a known target or infrequent focal CNAs may not be
identiﬁed. With GISTIC2.0, discrimination between somatic and germ
line copy number changes is based on comparison to a list of known
CNVs, which is not provided with the software. A list of known CNVs
such as those published in the database of genomic variants [1] can be
applied for this purpose. WIFA is a software package for the identiﬁca-
tion of focal CNAs and associated genes [42]. Similar to GISTIC2.0,
WIFA is based on amplitude and frequency of aberrations, but in con-
trast to GISTIC2.0,WIFA ﬁrst identiﬁes the CNAs in each sample individ-
ually prior to summation of the log2 ratios. This improves the detection
of CNAs in complex regions since neighboring CNAs detected in individ-
ual samples will be reported as two separate events (in GISTIC2.0, two
such events may not always be discernible). However, WIFA does not
discriminate between CNVs and focal CNAs. The software package
CGHcall, developed within our own research group, uses segmented
data, which can be obtained by the CBS algorithm [39], and then
classiﬁes copy number changes into separate states: homozygous
deletion, loss, neutral, gain or ampliﬁcation [40]. This enables CGHcall
to identify both low-frequency focal CNAs and single-copy number
changes. However, CGHcall is more sensitive to technical noise and
requires a cutoff to distinguish large from focal CNAs. Furthermore,
CGHcall, like WIFA, does not discriminate between CNVs and focal
CNAs. The best method to reliably discriminate between somatic focal
CNAs and germ line CNVs is by a direct comparison between the
tumor sample with the patient-matched germ line DNA. Unfortunately,
the use of patient-matched germ line DNA has not been optimally
implemented in any of the software tools described. We have recently
released an extension of the CGHcall algorithm as an R-package
(https://github.com/OscarKrijgsman/focalCall) to overcome this
limitation, and have used it to produce the results shown in Fig. 3.
With the tools described, new discoveries can be made in existing
data, thereby underlining the importance of public access to genome
wide screening data, which large consortia such as TCGA [43] and
ICGC (icgc.org) systematically facilitate. GEO [44] and ArrayExpress
[45] provide the facilities to publish raw and processed genomic data
accessible to anyone in the research community.
Fig. 2. Histogram of DNA copy number aberrations found in the HapMap samples (top, n = 270) and gastrointestinal cancers (bottom, n = 331). X-axis represent the size of the
aberrations in Mb, y-axis represents the frequency in the data sets. Grey bars under the plots indicate the size range of somatic focal CNAs and CNVs.
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DNA copy number detection plays an important role in cancer
research, enabling the discovery of new cancer driver genes, the delin-
eation of new cancer subtypes and patient stratiﬁcation [46]. However,
prior to the introduction of array techniques, identiﬁcation of cancer
driver genes in aberrant chromosomal regions was a challenge due to
the low resolution,which caused a high number of genes being detected
in each CNA.
Unlike other genetic aberrations, focal CNAs are thought to be
favored during tumor development and progression by an evolutionary
process [3,47]. Following this line of thought, Leary and collaborators
reasoned that, since focal CNAs only contain a limited number of
genes, they should be highly enriched for cancer driver genes, which
they consequently observed in the xenografts and low-passage cell
lines they studied [28]. Furthermore, Bignell et al. observed an
enrichment of cancer driver genes in focal CNAs in cancer cell lines
[33]. Both Bignell et al. and Leary et al. included ampliﬁcations and
homozygous deletions in the analysis, but not hemizygous focal losses
or single copy gains. However, focal deletions seen in clinical samples
are predominantly hemizygous, whereas homozygous focal deletions
are an exception. Multiple studies in a variety of cancer types,
e.g. colorectal carcinoma, cervical carcinoma, head and neck squamous
cell carcinoma, lymphoma and glioblastoma multiforme, have
conﬁrmed that hemizygous aberrations are often enriched for cancer
driver genes [28,34,36,37,48,49].
Additional functional or (epi)genetic analysis is required to further
separate driver from passenger genes in focal CNAs. For example, the
tumor suppressor gene PTEN is often found to be deleted, but can also
be mutated. Leary et al. [28] made use of this concept by analysing
both focal CNAs as well as point mutations across a series of 81 breast
and colon cancer samples. Genes that were frequently mutated were
regarded as putative tumor driver genes within the focal CNAs. This
approach enabled a genome-wide inventory of putative cancer driver
genes and identiﬁed genes that had not previously been associated
with carcinogenesis. To further support the role of these putative driver
genes in cancer development, several independent groups performed
functional assays. For example, RUNX1 is detected in focal deletions onchromosome 21q22.12 in 15% of esophageal cancer samples [38];
overexpression of RUNX1 in an esophageal cancer cell line with a focal
loss at 21q22.12 gave a strong reduction in anchorage-independent
growth. Conversely, in an esophageal cancer cell line without
this focal loss, ectopic expression of RUNX1 did not inﬂuence
anchorage-independent growth. This suggests that RUNX1 might
be a driver gene in this particular genetic background with a focal
aberration at 21q22.12, and supports its role as a tumor suppressor
gene in esophageal cancer [38].
In a study on cervical cancer precursor lesions, we aimed to dis-
tinguish between driver and passengers alterations for a recurrent
focal loss of ~50 kb at chromosome 2q35 encompassing three
genes (miRNA-375, FEV and CRYBA2) [34]. Of these three genes,
miR-375 expression was found to be down-regulated in cervical (pre)
cancerous lesions and ectopic expression in cervical cancer cell lines
was shown to reduce cell viability, suggesting that miRNA-375 might
be a pathogenic driver for focal CNA at 2q35. In the same study, a recur-
rent focal gain at 20q13.12, which encoded two genes (ZMYND8 and
EYA2), was reported. Upon siRNA-mediated silencing and cell viability,
migration and anchorage independent growth analysis, EYA2was sug-
gested to be the driver gene of the focal CNA and identiﬁed as a putative
new oncogene in cervical cancer. A similar strategy was applied in Day
et al. and detected a focal gain of IRS2 at chromosome 13q34 in colorec-
tal cancer, which positively correlates with progression from adenoma
to carcinoma. In vitro experiments demonstrated that deregulated
IRS2 expression activates the oncogenic PI3 kinase pathway and in-
creases cell adhesion [50]. Focal loss of a ~20 kb region of chromosome
1q is detected by arrayCGH in 38% of localized prostate cancers and in
67% of metastatic prostate cancers as well as in breast, ovarian, colon
and lung cancers [51]. The only annotated element in this region is
miRNA-101-1, which is a regulator of expression of the polycomb
gene, EZH2.
These examples primarily concern focal CNAs that contain complete
genes. However, focal CNAsdo not necessarily span anentire gene. Focal
CNAs of 15 kb or less encompassing only one or a few exons of PTEN or
RB1 in breast cancer have been reported [31]; focal gain of exon two of
PTEN leads to loss of expression for all downstream exons. Acquired
focal loss of one or a few exons is also observed at some genes located
Fig. 3. Focal CNA and CNV in a lung tumor. Panel A represents the DNA copy number proﬁle of a lung tumor generated with next-generation sequencing (coverage ~ 0.2). Panel B shows
chromosomes 9 and 16 for both tumor (top) andmatched patient germ line DNA (bottom). A focal CNA on chromosome 9 (CDKN2A) is present in the tumor sample but not in the patient
germ line DNA. A CNV on chromosome 16 is present in both tumor and in the patient germ line DNA. The x-axis represents the probes according to genomic locations, and the y-axis the
log2 ratios of the probes. Red lines represent the CBS segments [39].
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and PARK2 [32,52].
CNAs serve as important predictive and/or prognostic biomarkers
in the clinic. A classic example is the ampliﬁcation at 17q12 of HER2,
observed in ~15% of breast cancer patients. HER2-positive patients can
be treated with Herceptin, an antibody that interferes with the HER2
receptor [53]. Another classic example is the ampliﬁcation at 2p24
of MYCN in neuroblastoma [54]. Ampliﬁcation of MYCN is a negative
prognostic biomarker for the survival of these patients. Moreover,
it provides an important indicator for an aggressive treatment regime.
Both cases demonstrate high-level focal CNAs commonly referred to
as ampliﬁcations. These ampliﬁcations are of special interest as these
may contain drugable oncogenes. However, it should be noted that
the HER2 ampliﬁcation often exceeds 3 Mb, which does not ﬁt within
the spatial limitations we deﬁned for focal CNAs and demonstrates the
limitations of a strict boundary. As a result of the size and amplitude,
such high-level ampliﬁcations were already discovered prior to the
introduction of arrayCGH and are summarized in a review by Santarius
et al. [2].
Other predictive or prognostic examples are a focal loss of PTPRS
and its concurrent decrease in expression being predictive of tyrosine
kinase inhibitor (TKI) response in head and neck squamous cell
carcinomas [55]; 8 focal CNAs in a series of 38 colorectal cancer
were associated with poor survival [48] and homozygous focaldeletions in hepatocellular carcinomas that are signiﬁcantly associated
with tumor aggressiveness and poor survival [56]. In melanomas, the
presence of focal CNAs, including “chromothripsis” (see next section),
is a marker for poor outcome [57].
5. Focal CNAs as passenger events
Each of the studies described above builds on the assumption that a
driver gene within a focal CNA is clinically relevant. However, Müller
and colleagues reason that even passenger genes within focal CNAs
may also serve as therapeutic targets [58]. These authors reason that
genes that carry out an essential role in the cell and are part of a family
of genes that are redundant to each other could provide cancer-speciﬁc
vulnerabilities. Silencing the passenger gene ENO2 is tolerated by a
healthy cell, but not by glioblastoma multiforme (GBM) cell lines that
already have a homozygous focal deletion of the gene family member
ENO1. In GBM cell lines, the silencing of ENO2 inhibits growth, survival
and tumorigenic potential in these cells and might provide an effective
treatment strategy.
Rather than being evolutionarily driven, focal CNAs could be
a footprint of genomic rearrangements [59,60]. For example,
“chromothripsis” (a phenomenon that was carefully deﬁned by
Korbel and Campbell [61] although not all articles published on
“chromothripsis” adhere to their deﬁnition) gives rise to extensive
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result in multiple focal CNAs, although these would not necessarily
affect driver genes [57,62]. In this scenario, “chromothripsis” would
confer a selective advantage, and many focal passenger CNAs can arise
as a consequence of the extensive genomic rearrangements. The same
may be true for focal CNAs that harbor extensive genomic rearrange-
ments in multiple regions at once, referred to as “chromoplexy” [63].
Focal CNAs regularly arise at common fragile sites (CFS) [64]. These
genomic regions are prone to DNA breakage, which occurs when cells
are under replication stress. Focal CNAs in CFS predominantly concern
deletions and frequently encompass large genes including MACROD2,
A2BP1 and CSMD1 [60]. For many of those genes, a clear relation with
cancer has not been established and therefore observed focal CNAs in
CFS are likely to be passenger events. Conversely, the genes PARK2,
FHIT andWWOX, which all have a CFS, are lost by focal CNAs in multiple
cancer types and are thought to be tumor suppressor genes [32,64].
6. Conclusion and future perspective
The frequent occurrence of focal genomic aberrations in cancer has
provided us with an excellent possibility to pinpoint candidate genes
involved in cancer development and progression. In addition to a better
understanding of cancer biology, detection of focal CNAs can also lead to
the identiﬁcation of new therapeutic targets or biomarkers for patient
stratiﬁcation. At present, CNAs are best deﬁned based on the size of
the aberration as a molecular or biological deﬁnition to classify focal
CNAs as a separate entity has not been identiﬁed. Based on operational
considerations, we favor a cutoff of ≤3 Mb for focal CNAs.
Despite the fact that current studies on focal CNAs reveal a remark-
able enrichment for known cancer genes, the analysis thereof might
suffer from the same problems as observed with mutation analysis
[65]: as the number of studies and samples increases, the list of putative
genes also increases with few of these genes likely to be of clinical
relevance. This emphasizes the notion that genes detected in focal
aberrations will need thorough validation to prove their biological
and/or clinical relevance. A further increase in gene candidates is
expected based on the current shift from array-based methods to NGS.
In addition to an increase in resolution and better insights into the
structural mechanisms, advances in sequencing techniques can also
open the vaults of archival FFPE tissue with extensive follow-up data.
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